These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6352655)

  • 1. A random comparative trial of 0.25, 0.5 and 1.0 g ceftazidime twice daily in urinary tract infection.
    Gentry LO; Douthit MB; Childs SJ; Madsen PO
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():53-7. PubMed ID: 6352655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of ceftazidime and tobramycin in the treatment of complicated urinary tract infections.
    Cox CE
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():47-52. PubMed ID: 6352654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefamandole and cefazolin in the therapy of complicated urinary tract infections.
    Hoyme U; Madsen PO
    J Infect Dis; 1978 May; 137 Suppl():S100-S102. PubMed ID: 349091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftazidime in the treatment of urinary tract infection.
    Kasanen A; Nikoskelainen J; Saarimaa H; Toivanen P
    Curr Med Res Opin; 1982; 8(4):266-73. PubMed ID: 6817972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cefazolin. 3. Double blind controlled trial in urinary tract infections].
    Seika K; Minakawa M; Miyoshi K; Yamaji K; Sugiyama Y
    Jpn J Antibiot; 1972 Apr; 25(2):72-8. PubMed ID: 4627212
    [No Abstract]   [Full Text] [Related]  

  • 6. An open study of the use of ceftazidime in Gram-negative infections.
    Wardle JK; Snow MH; Ingham HR; Selkon JB
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():389-93. PubMed ID: 6352650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cephalexin monohydrate in the treatment of urinary tract infections and urethritis.
    Rocha H; Peltier Queiroz F
    Prensa Med Mex; 1970; ():56-60. PubMed ID: 4931118
    [No Abstract]   [Full Text] [Related]  

  • 8. Ceftazidime in the treatment of pediatric patients with severe urinary tract infections due to Pseudomonas spp.
    Rusconi F; Assael BM; Florioli A; Zaffaroni G
    Antimicrob Agents Chemother; 1984 Mar; 25(3):395-7. PubMed ID: 6372686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open study of ceftazidime in serious infections due to multiply-resistant bacteria.
    Pechère JC; Delisle R
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():181-8. PubMed ID: 6352619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the usefulness of a novel injectable cephalosporin, E1040, and ceftazidime for management of complicated urinary tract infections caused by Pseudomonas aeruginosa and Proteus mirabilis by using the rat urolithiasis model.
    Satoh M; Munakata K; Takeuchi H; Yoshida O
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1580-3. PubMed ID: 1510458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
    Gentile I; Maraolo AE; Borgia G
    Expert Rev Anti Infect Ther; 2016 Oct; 14(10):875-8. PubMed ID: 27599088
    [No Abstract]   [Full Text] [Related]  

  • 12. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
    Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
    Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of ceftazidime. Treatment of serious infection due to multiresistant Pseudomonas and other gram-negative bacteria.
    Scully BE; Neu HC
    Arch Intern Med; 1984 Jan; 144(1):57-62. PubMed ID: 6419690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftazidime therapy of infections caused by Enterobacteriaceae and Pseudomonas aeruginosa.
    Maslow MJ; Rosenberg A; Pollock AA; Press RA; Silverman D; El-Sadr W; Richmond AS; Simberkoff MS; Rahal JJ
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():213-7. PubMed ID: 6413486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftazidime as a single agent in the treatment of severe Pseudomonas aeruginosa infections.
    Clumeck N; Gordts B; Dab I; Jaspar N; Van Laethem Y; Butzler JP
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():207-11. PubMed ID: 6352620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complicated urinary tract infections treated with ceftazidime and tobramycin: a comparative study.
    Madsen PO; Frimodt-Møller PC
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():77-9. PubMed ID: 6352658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open study of the safety and efficacy of enoxacin in complicated urinary tract infections.
    Foot M; Williams G; Want S; Roe M; Quaghebeur G; Bates S
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():97-103. PubMed ID: 3129393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections.
    Armstrong ES; Mikulca JA; Cloutier DJ; Bliss CA; Steenbergen JN
    BMC Infect Dis; 2016 Nov; 16(1):710. PubMed ID: 27887579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with ceftazidime in urology in Japan.
    Kawamura N
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():65-70. PubMed ID: 6352657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cefotaxime in septicaemia and severe infections due to multiresistant Gram-negative bacilli (author's transl)].
    Dureux JB; Canton P; Roche G; Weber M; Gérard A
    Nouv Presse Med; 1981 Feb; 10(8):601-6. PubMed ID: 6259602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.